SUSD2 and ovarian carcinoma: HGSOC is the most commonly diagnosed and is considered the deadliest of ovarian carcinoma subtypes with <40% of HGSOC patients surviving 5 years after initial diagnosis.3 To investigate the effect of SUSD2 on overall survival of HGSOC patients, a clinically annotated TMA containing 128 primary tumors from patients diagnosed with HGSOC was analyzed by IHC using an anti-SUSD2 antibody (Figures 2a–c).